多发性骨髓瘤治疗:ASCO动态指南2026.1.1版
ASCO动态指南针对多发性骨髓瘤治疗领域,由常设专家小组持续系统审查文献并定期更新推荐。本版本为2026.1.1版,旨在为临床实践提供基于最新证据的推荐,但不替代临床医生的独立专业判断。
要点
- ASCO动态指南针对多发性骨髓瘤治疗,定期更新推荐。
- 由常设专家小组持续系统审查健康文献。
- 推荐不替代临床医生的独立专业判断。
核心结论
- ASCO动态指南为多发性骨髓瘤治疗提供定期更新的推荐,基于持续文献审查。
研究设计与样本
- 由常设专家小组按照ASCO指南方法学手册,持续系统审查健康文献并定期更新。
临床怎么用
- 临床医生可参考该动态指南获取多发性骨髓瘤治疗的最新推荐,但需结合患者个体情况独立判断。
局限性
- 动态指南不替代治疗临床医生的独立专业判断,且未考虑患者个体差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Living guidelines are developed for selected topic areas with rapidly evolving evidence that drives frequent change in recommended clinical practice. Living guidelines are updated on a regular schedule by a standing expert panel that systematically reviews the health literature on a continuous basis, as described in the ASCO Guidelines Methodology Manual. ASCO Living Guidelines follow the ASCO Conflict of Interest Policy Implementation for Clinical Practice Guidelines. Living Guidelines and updates are not intended to substitute for independent professional judgment of the treating clinician and do not account for individual variation among patients. See appendix for disclaimers and other important information (Appendix 1 and Appendix 2). Updates are published regularly and can be found on the ASCO Publications website.
引用
- Banerjee R, Cheung MC, Derman B, et al. Treatment of Multiple Myeloma: ASCO Living Guideline, Version 2026.1.1. J Clin Oncol. 2026. PMID: 42160714. doi:10.1200/JCO-26-01139
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。